Medio Labs offers a diagnostic platform, MedioSeq, that enables clinical laboratories to perform pathogen diagnostics, replacing traditional qPCR methods. This technology allows for more efficient and potentially comprehensive molecular testing in CLIA/CAP-certified labs.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional pathogen diagnostics in clinical laboratories often rely on qPCR methods, which can be inefficient and limited in scope for comprehensive molecular testing. This can lead to slower turnaround times and potentially miss less common pathogens.
Solution
Medio Labs offers MedioSeq, a diagnostic platform designed to enable clinical laboratories to perform more efficient and comprehensive pathogen diagnostics, replacing traditional qPCR methods. MedioSeq leverages advanced sequencing technology to identify a wide range of pathogens in a single assay, improving the speed and accuracy of diagnosis. The platform is designed for seamless integration into CLIA/CAP-certified labs, providing a streamlined workflow for molecular testing. By offering a more comprehensive and efficient approach to pathogen detection, MedioSeq aims to improve patient outcomes and reduce healthcare costs.
Target Audience
The primary customers are clinical laboratories seeking to improve the efficiency and comprehensiveness of their pathogen diagnostics.
Features
- Advanced sequencing technology for broad pathogen detection
- Streamlined workflow for CLIA/CAP-certified labs
- Single assay for multiple pathogen identification
- Improved speed and accuracy compared to traditional qPCR methods